SFSpencer Frome

Spencer Frome

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Spencer Frome has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Translational Inefficiencies in Traumatic Brain Injury Research: Evidence From 94 399 Publications

    by Daniel N. de Souza, Spencer Frome, Eric A. Grin, Scott N. Grossman, Paul P. Huang, David B. Kurland

    BACKGROUND AND OBJECTIVES: Despite extensive investigation, no proven neuroprotective therapy exists for traumatic brain injury. Although this translational gap has been widely discussed, it has not been objectively characterized through systematic analysis. We hypothesized that this deficit reflects not only biological intractability but also constraints within the research ecosystem that impede translational progress. METHODS: Web of Science, PubMed, and Scopus were searched without date or document type restrictions. A natural language processing pipeline screened results and classified study designs, topical areas, geographic affiliations, and funding sources. All analyses and visualizations were performed using open-source Python libraries. RESULTS: 94 399 publications spanning 1829 to 2026 comprised the corpus. Research output was geographically concentrated. Thematic network analysis revealed 4 discrete research domains (preclinical, acute clinical, chronic/rehabilitation, and sports-related), with the preclinical domain spatially isolated from all 3 clinical clusters. Randomized controlled trials comprised 1.5% of publications, while reviews exceeded 20% of annual output throughout the 21st century. Preclinical research share peaked near 23% of annual publications around 2000 and subsequently declined without a commensurate rise in clinical trial activity (Chow test, P < .001). Diagnostic biomarker research comprised 3.8% of publications but remained poorly integrated with prospective trial designs. Postacute pharmacotherapy research represented 0.8% of publications and the smallest trial-integrated fraction of any area examined. Citation concentration was substantial (Gini 0.725), with nearly one-fifth of publications uncited. Journal-level analysis revealed a sustained decline in neurosurgery-specific journal representation from 1980 to 2025; in 1993, neurology and neuroscience journals surpassed neurosurgery journals in proportional share of annual publications and have maintained that lead since. National Institutes of Health–funded research, the largest funder by a factor of 5, produced randomized controlled trial rates indistinguishable from those of unfunded literature (1.6%). CONCLUSION: Traumatic brain injury literature has grown substantially without commensurate advances in high-evidence research, reflecting identifiable inefficiencies in infrastructure and funding strategy that represent targets for intervention.

  • The Treatment of Subdural Collections in Patients With Shunted Normal Pressure Hydrocephalus: A Single-Center Experience

    by Spencer Frome, Daniel N. de Souza, Amogh Iyanna, Hammad A. Khan, Benjamin Hammond, Eric A. Grin, Antonio Malaspina, Carter Suryadevara, Adhith Palla, Alexander Eremiev, et al.

    BACKGROUND AND OBJECTIVES: Normal pressure hydrocephalus (NPH) affects approximately 0.2% to 2.9% of adults older than 65 years and is characterized by progressive gait impairment, cognitive decline, and urinary incontinence. Cerebrospinal fluid shunting is the mainstay of treatment but carries a risk of overdrainage, leading to subdural collections. Evidence guiding the management of these collections in patients with shunted NPH remains limited. We aimed to characterize treatment strategies and outcomes for subdural collections in patients with shunted NPH and to propose a practical management framework for nonemergent presentations. METHODS: We performed a retrospective cohort study of patients with shunted NPH who developed subdural collections requiring treatment between January 2014 and September 2025. Interventions included valve pressure adjustment, middle meningeal artery (MMA) embolization, and surgical evacuation. Clinical, radiographic, and treatment data were extracted from the electronic health record. Time-to-resolution and recurrence were assessed using Kaplan–Meier analysis. Receiver operating characteristic analysis determined the predictive value of baseline collection volume for failure of valve adjustment. RESULTS: Sixty patients with 96 total collections underwent 91 valve pressure increases, 8 craniotomies for 8 collections, 23 MMA embolization procedures for 32 collections, and 15 subdural evacuating port system procedures for 16 collections. The median time to resolution for collections that underwent valve adjustment only, MMA embolization without evacuation, evacuation without MMA embolization, and both MMA embolization and evacuation was 1.91, 3.99, 1.77, and 5.17 months, respectively. Using pretreatment volume to predict valve adjustment failure demonstrated an area under the curve of 0.75 with an optimal cutoff of 40.05 cm 3 , corresponding to a sensitivity of 75.0% and a specificity of 71.4%. CONCLUSION: Baseline hematoma volume may help identify which shunted NPH patients with subdural hematomas are at higher risk of failing valve adjustment alone. We propose a volume-informed management framework in which larger hematomas (approximately >40 cm 3 ) prompt earlier consideration of treatment escalation.

  • Stereotactic Navigation and Intracranial Hemorrhage Risk Following Ventricular Catheter Placement: A Single-Center Cohort Study

    by Daniel N. de Souza, Spencer Frome, Eric A. Grin, Adhith Palla, Alexander Eremiev, Caroline Kremer, Jeffrey H. Wisoff, Yosef M. Dastagirzada, Eveline Teresa Hidalgo, David H. Harter

    BACKGROUND AND OBJECTIVES: Cerebrospinal fluid shunting is a common treatment for hydrocephalus. Several techniques for ventricular catheter placement exist, yet comparative safety data remain limited. This study evaluated whether stereotactic navigation-assisted ventricular catheter placement is associated with reduced 30-day postoperative intracranial hemorrhage (ICH) rates. METHODS: This was a retrospective analysis of adults who underwent frontal or occipital shunt placement for hydrocephalus between 2014 and 2023. The primary exposure variable was the use of stereotactic navigation for ventricular catheter placement. The primary outcomes were hospital length of stay (LOS) and 30-day postoperative ICH. RESULTS: A total of 541 shunt placements were included (median age 72.5 years; 51.6% male). Normal pressure hydrocephalus represented the most common underlying diagnosis (60.3%). Stereotactic navigation was used in 221 cases (40.9%) and was more frequently employed in younger patients (66.0 vs 73.9 years; P < .001), more recent years (median 2021 vs 2019; P < .001), and cases involving non-normal pressure hydrocephalus diagnoses ( P < .001). Overall, 12 patients (2.2%) developed ICH within 30 days of surgery. The 30-day ICH rate was significantly lower with stereotactic navigation (0.5% vs 3.4%; odds ratio 0.13, 95% CI 0.02-1.00; P = .033), corresponding to an absolute risk reduction of 2.99% and a number needed to treat of 34. Kaplan-Meier analysis demonstrated superior hemorrhage-free survival with navigation-assisted placement (log-rank P = .021), with most events occurring within the first 14 days postoperatively. Propensity-matched analysis demonstrated a similar effect size but fell short of statistical significance. Navigation use was not independently associated with LOS or any other complications. CONCLUSION: Stereotactic navigation-assisted ventricular catheter placement was associated with lower rates of 30-day postoperative ICH compared with non-navigation–assisted placement, with a number needed to treat of 34. Given the absence of adverse effects on LOS or overall complication rates, these findings support routine consideration of neuronavigation during shunt placement when available.

  • Incidence and predictors of hemorrhage in pediatric low-grade glioma

    by Eric A. Grin, Spencer Frome, Joseph Turner, Jessica Clymer, Yosef Dastagirzada, David H. Harter, Sharon Gardner, Eveline Teresa Hidalgo, Devorah Segal

    Purpose Pediatric low-grade gliomas (pLGGs) typically have excellent long-term outcomes; intratumoral hemorrhage is a rare, potentially dangerous complication. Hemorrhage risk in the context of molecular alterations and targeted therapies remains poorly characterized. We analyzed the incidence, timing, and independent risk factors for hemorrhage in a large contemporary pLGG cohort. Methods We conducted a retrospective cohort study of 236 children with pLGG treated at a single center (2011–2025). Clinical, radiographic, and molecular variables were abstracted. The primary endpoint was spontaneous tumoral hemorrhage. Time-to-event analyses utilized Kaplan–Meier methods and Cox proportional hazards modeling; penalized regression mitigated overfitting given the event rarity. Results Twelve patients (5.1%) experienced hemorrhage over 2,234 person-years (incidence: 0.54/100 person-years). Hemorrhage typically occurred years after initial tumor diagnosis (median 6.4 years). The presence of a KIAA1549::BRAF fusion in the tumor had the strongest association with hemorrhage, persisting across multivariable models (approximately sixfold increased risk), although estimates were limited by low event number. MAPK inhibitor exposure (specifically binimetinib and tovorafenib) was associated with hemorrhage in univariate analysis but partially confounded by fusion status. CSF diversion independently increased risk at brainstem, optic pathway, and hypothalamic locations. No hemorrhages occurred among patients with underlying genetic syndromes, including neurofibromatosis type 1 and tuberous sclerosis. Conclusion Hemorrhage in pLGG is an infrequent late complication associated with tumor biology. KIAA1549::BRAF fusion may identify a higher-risk subgroup, with MAPK inhibitor exposure and CSF diversion further modifying risk. These findings support biology-informed surveillance and personalized management strategies for at-risk children.

  • Safety and Efficacy of Expedited Discharge Protocols After Endoscopic Endonasal Pituitary Surgery: A Single-Center Cohort Study

    by Daniel N. de Souza, Spencer Frome, Qing Wen, Carter M. Suryadevara, Rajeev D. Sen, Carlos D. Pinheiro-Neto, Seth M. Lieberman, Richard A. Lebowitz, Dimitris G. Placantonakis, Chandra Sen, et al.

    BACKGROUND AND OBJECTIVES: Little is known about how accelerated discharge strategies compare with established enhanced recovery pathways after endoscopic endonasal surgery (EES). This study aimed to evaluate the efficacy and safety of an accelerated discharge protocol after EES. METHODS: This was a retrospective analysis of adults who underwent EES for pituitary adenomas at a single academic center between 2012 and 2025. Patients were managed under 1 of 4 postoperative pathways dependent on year of surgery: (1) No institutional protocol; (2) First-generation recovery protocol; (3) Enhanced recovery after surgery (ERAS); and (4) Expedited one-day discharge. Demographic and clinical variables were extracted from the electronic medical record using automated natural-language–processing methods. Primary outcomes were length of stay (LOS) and 30-day all-cause readmission or reoperation. All data processing, visualization, and statistical analyses were performed using Python version 3.12. RESULTS: Six hundred patients who underwent 630 surgeries were included. Median LOS was 3 days, with a 30-day readmission rate of 14.3% and a 30-day postdischarge reoperation rate of 2.5%. LOS differed significantly across protocol eras, with progressively shorter hospital stays observed over time and the shortest median stay occurring under the expedited discharge protocol ( P < .0001). Readmission rates were highest in the preprotocol (16.2%) and initial protocol periods (17.2%), declining to 8.3% under the ERAS protocol and 10.0% under the expedited discharge protocol ( P = .039). 30-day postdischarge reoperation rates did not statistically differ across protocols. In multivariate analyses, both the ERAS (rate ratio = 0.899, P = .021) and expedited discharge protocols (rate ratio = 0.819, P = .024) demonstrated significantly shorter hospital stays compared with the preprotocol era, without differences in 30-day readmission or reoperation rates. CONCLUSION: The expedited discharge protocol safely shortened hospital stays without increasing 30-day readmissions or reoperations. These findings support the feasibility of accelerated postoperative pathways after EES. Broad adoption has the potential to produce substantial resource savings without compromising patient safety.

  • The Impact of Programmable Valves on the Risk and Severity of Subdural Collections in Patients With Normal Pressure Hydrocephalus

    by Spencer Frome, Jeffrey H. Wisoff, Hammad A. Khan, Amogh Iyanna, Benjamin Hammond, Eric A. Grin, Antonio Malaspina, Carter Suryadevara, Daniel N. de Souza, Adhith Palla, et al.

    BACKGROUND AND OBJECTIVES: Normal pressure hydrocephalus (NPH) is characterized by the classic triad of cognitive decline, gait instability, and urinary incontinence in the setting of ventriculomegaly with normal intracranial pressure. Cerebrospinal fluid diversion is the current standard treatment, yet it carries a risk of overdrainage, resulting in subdural hematoma or hygroma. Different valves have been developed to mitigate this risk, yet consensus remains unclear regarding optimal valve for NPH. METHODS: We performed a retrospective cohort study on all patients with NPH who underwent cerebrospinal fluid shunting or revision between January 2014 and September 2025 at our institution. Demographic, clinical, and radiological data were collected from the electronic health record. Kaplan–Meier survival analysis, univariate logistic regression, and multivariate modeling were used to identify predictors of subdural collections and the need for surgical treatment. RESULTS: Since our change in practice from the Integra NPH Low Flow Valve (Low Flow OSV) to other valves in 2022, we observed a rise in symptomatic subdural collections. Programmable valves were associated with a markedly increased 1-year risk of both subdural collection formation and need for surgical intervention compared with the Low Flow OSV. Overall, Certas and Strata valves demonstrated higher rates of subdural collections requiring surgery than the Low Flow OSV (14.6% vs 2.1%, P < .001; 10.5% vs 2.1%, P = .005, respectively). On multivariate analysis, both the Strata and Certas valves were independently associated with increased odds of developing any subdural collection and necessitating surgery. Vascular disease and dual antiplatelet therapy also increased risk. CONCLUSION: In this large single-center cohort study, programmable valves, specifically the Certas and Strata, were associated with an increased rate and severity of subdural collections compared with the Low Flow OSV. The use of low-flow designs may mitigate complications for the NPH population, and the use of lower programmable valve settings should be carefully considered.

  • The cyclimids: Degron-inspired cereblon binders for targeted protein degradation

    by Saki Ichikawa, N. Connor Payne, Wenqing Xu, Chia-Fu Chang, Nandini Vallavoju, Spencer Frome, Hope A. Flaxman, Ralph Mazitschek, Christina M. Woo